Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared ASTCT’s post on LinkedIn, adding:
“Always proud of our superstar pharmacist leader Zahra Mahmoudjafari!
Her outstanding work, innovation, and dedication are helping shape the future of cellular therapy.”
Quoting ASTCT’s post:
“Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, is the first author of the article ‘From Vision to Viability: Developing Infrastructure for Cell and Gene Therapy Programs.’ She shares in this Q&A background on how this research came about, findings that particularly surprised her, and how these findings are guiding current and future initiatives.
Other articles featuring Al-Ola Abdallah and ASTCT on OncoDaily.